Multiple myeloma, the second most common haematological malignancy after non-Hodgkin lymphoma, is characterized by the abnormal proliferation of plasma cells in the bone marrow. The malignant plasma cells crowd out normal blood cells, which can lead to low blood counts, bone destruction and renal damage. New drugs for multiple myeloma have transformed treatment in the past decade and agents in the pipeline promise further advances.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or